TEV-48574

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

22 competitors in Crohn Disease

#DrugCompanyPhaseTrials

1

Tremfya

Johnson & Johnson

Approved

42

Omvoh

Eli Lilly

Approved

23

Stelara

Johnson & Johnson

Phase 3

44

Skyrizi

AbbVie

Phase 3

15

Medrol

Pfizer

Phase 2

16

Entyvio

Takeda

Phase 2

17

Rituxan

Roche

Phase 2

18

Cytoxan

BBaxter Healthcare Corporation

Phase 2

19

Clolar

GGenzyme, a Sanofi Company

Phase 2

110

Kepivance

SSwedish Orphan Biovitrum

Phase 2

1Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Completed·Teva·Phase 2·NCT05499130·290 enrolled

Asthma1 trial

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Terminated·Teva·Phase 2·NCT04545385·65 enrolled

Crohn Disease1 trial

A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)

Active, not recruiting·Teva·Phase 2·NCT05668013·247 enrolled

Details

Drug Info

Related News